Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
60505-6272-01 60505-6272 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 1, 2023 In Use
60505-6277-00 60505-6277 CISplatin CISplatin 50.0 mg/50mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 6, 2023 In Use
63759-3048-01 63759-3048 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63759-3049-01 63759-3049 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
63759-3050-01 63759-3050 Pemetrexed disodium Pemetrexed 1000.0 mg/100mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 3, 2023 In Use
66658-0113-03 66658-0113 Palifermin KEPIVANCE 5.16 mg/1.2mL Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF Intravenous Aug. 4, 2023 In Use
66658-0113-06 66658-0113 Palifermin KEPIVANCE 5.16 mg/1.2mL Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF Intravenous Aug. 4, 2023 In Use
68083-0515-01 68083-0515 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 13, 2023 In Use
68083-0516-01 68083-0516 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 13, 2023 In Use
68083-0517-10 68083-0517 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 22, 2023 In Use
68083-0560-10 68083-0560 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 22, 2023 In Use
69639-0106-01 69639-0106 Fosnetupitant and Palonosetron AKYNZEO 260.0 mg/20mL, 0.28 mg/20mL Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist, Substance P/Neurokinin 1 Intravenous Aug. 1, 2023 In Use
70121-2453-01 70121-2453 Pemetrexed disodium PEMRYDI RTU 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 6, 2023 In Use
70121-2461-01 70121-2461 Pemetrexed disodium PEMRYDI RTU 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 6, 2023 In Use
70121-2462-01 70121-2462 Pemetrexed disodium PEMRYDI RTU 1000.0 mg/100mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 6, 2023 In Use
70436-0209-80 70436-0209 Levoleucovorin injection LEVOLEUCOVORIN CALCIUM 10.0 mg/mL Ancillary Therapy Chemoprotective Antidote Intravenous Aug. 1, 2023 In Use
70436-0210-80 70436-0210 Levoleucovorin injection LEVOLEUCOVORIN CALCIUM 10.0 mg/mL Ancillary Therapy Chemoprotective Antidote Intravenous Aug. 1, 2023 In Use
70860-0228-61 70860-0228 Melphalan hydrochloride Melphalan Hydrochloride 50.0 mg/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Sept. 1, 2023 In Use
71288-0102-10 71288-0102 Bendamustine HCl Bendamustine 25.0 mg/5mL Chemotherapy Alkylating Agent Purine analog Intravenous June 5, 2023 In Use
71288-0103-20 71288-0103 Bendamustine HCl Bendamustine 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 5, 2023 In Use
71288-0409-05 71288-0409 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Aug. 14, 2023 In Use
73441-0800-04 73441-0800 omidubicel-onlv OMISIRGE Ancillary Therapy Immunostimulant Stem cell mobilizer Intravenous May 1, 2023 In Use
72266-0252-01 72266-0252 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 11, 2023 In Use
72266-0253-01 72266-0253 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 11, 2023 In Use
81607-0005-11 81607-0005 Arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 31, 2023 In Use
81607-0006-07 81607-0006 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 31, 2023 In Use
81952-0911-01 81952-0911 FOSAPREPITANT FOSAPREPITANT 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous July 14, 2023 In Use
82243-1001-01 82243-1001 FOSAPREPITANT FOCINVEZ 150.0 mg/50mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 30, 2023 In Use
82511-0006-60 82511-0006 CARBOPLATIN CARBOPLATIN 600.0 mg/60mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 24, 2023 In Use
55390-0142-10 55390-0142 Daunorubicin Hydrochloride Daunorubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous July 13, 1998 Oct. 31, 2012 No Longer Used
55390-0215-01 55390-0215 Idarubicin Hydrochloride Idarubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 15, 2007 Sept. 30, 2011 No Longer Used
55390-0216-01 55390-0216 Idarubicin Hydrochloride Idarubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 15, 2007 Sept. 30, 2011 No Longer Used
55390-0217-01 55390-0217 Idarubicin Hydrochloride Idarubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 15, 2007 Sept. 30, 2011 No Longer Used
55390-0237-01 55390-0237 Doxorubicin Hydrochloride Adriamycin Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 1, 1996 June 30, 2014 No Longer Used
55390-0238-01 55390-0238 Doxorubicin Hydrochloride Adriamycin Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 1, 1996 June 30, 2014 No Longer Used
55390-0251-01 55390-0251 Mitomycin Mitomycin Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 1, 1996 Jan. 31, 2013 No Longer Used
55390-0252-01 55390-0252 Mitomycin Mitomycin Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 1, 1996 Jan. 31, 2013 No Longer Used
55390-0253-01 55390-0253 Mitomycin Mitomycin Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Sept. 1, 1999 Nov. 30, 2012 No Longer Used
55390-0291-01 55390-0291 Etoposide Etoposide Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous May 1, 1996 June 30, 2013 No Longer Used
59353-0002-10 59353-0002 Epoetin alfa-epbx RETACRIT 2000.0 [iU]/mL, 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59353-0003-10 59353-0003 Epoetin alfa-epbx RETACRIT 3000.0 [iU]/mL, 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59353-0004-10 59353-0004 Epoetin alfa-epbx RETACRIT 4000.0 [iU]/mL, 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59353-0010-10 59353-0010 epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL, 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59353-0120-10 59353-0120 Epoetin alfa-epbx RETACRIT 20000.0 [iU]/mL, 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Nov. 9, 2020 In Use
59353-0220-10 59353-0220 Epoetin alfa-epbx RETACRIT 10000.0 [iU]/mL, 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Nov. 9, 2020 In Use
60505-6166-00 60505-6166 clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 1, 2018 Jan. 31, 2025 In Use
61703-0360-18 61703-0360 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
61703-0360-22 61703-0360 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 Oct. 31, 2015 In Use
61703-0360-50 61703-0360 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 25, 2009 Jan. 31, 2016 In Use
67457-0847-44 67457-0847 Trastuzumab OGIVRI 420.0 mg/ 20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov. 29, 2019 April 30, 2027 In Use

Found 10,000 results in 4 milliseconds — Export these results